ACTA1 and Hepatic fibrosis: Overall, treatment with the miR-150 secretome reduced the expression of profibrogenic markers, such as α-SMA, MMP2, and TGF-β, more than that of the control secretome in both in vitro and in vivo models of liver fibrosis.